Switch theme
Sign up to access all valuation multiples
Global Health Ltd operates as a private multi-specialty tertiary care provider operating in the North and East regions of India, with key specialties of cardiology and cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopedics, liver transplant, and kidney and urology. Under the Medanta brand, it has a network of hospitals in operation (Gurugram, Indore, Ranchi, and Lucknow), a hospital that is under construction with an operational outpatient facility (Patna), and a hospital (Noida) planned for development. The Group operates Healthcare services as a single business segment in India, constituting a single geographical segment.
2004
6.8K+
LTM Revenue $443M
LTM EBITDA $106M
$3.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Medanta has a last 12-month revenue (LTM) of $443M and a last 12-month EBITDA of $106M.
In the most recent fiscal year, Medanta achieved revenue of $432M and an EBITDA of $106M.
Medanta expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Medanta valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $443M | XXX | $432M | XXX | XXX | XXX |
| Gross Profit | $338M | XXX | $329M | XXX | XXX | XXX |
| Gross Margin | 76% | XXX | 76% | XXX | XXX | XXX |
| EBITDA | $106M | XXX | $106M | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 25% | XXX | XXX | XXX |
| EBIT | $85.0M | XXX | $80.0M | XXX | XXX | XXX |
| EBIT Margin | 19% | XXX | 19% | XXX | XXX | XXX |
| Net Profit | $63.0M | XXX | $56.4M | XXX | XXX | XXX |
| Net Margin | 14% | XXX | 13% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $11.4M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Medanta's stock price is INR 1188 (or $14).
Medanta has current market cap of INR 319B (or $3.7B), and EV of INR 315B (or $3.7B).
See Medanta trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.7B | $3.7B | XXX | XXX | XXX | XXX | $0.24 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Medanta has market cap of $3.7B and EV of $3.7B.
Medanta's trades at 8.8x EV/Revenue multiple, and 35.0x EV/EBITDA.
Equity research analysts estimate Medanta's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Medanta has a P/E ratio of 59.3x.
See valuation multiples for Medanta and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.7B | XXX | $3.7B | XXX | XXX | XXX |
| EV (current) | $3.7B | XXX | $3.7B | XXX | XXX | XXX |
| EV/Revenue | 8.3x | XXX | 8.8x | XXX | XXX | XXX |
| EV/EBITDA | 34.7x | XXX | 35.0x | XXX | XXX | XXX |
| EV/EBIT | 43.3x | XXX | 46.3x | XXX | XXX | XXX |
| EV/Gross Profit | 10.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | 59.3x | XXX | 66.4x | XXX | XXX | XXX |
| EV/FCF | 400.2x | XXX | 482.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMedanta's last 12 month revenue growth is 16%
Medanta's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $37K for the same period.
Medanta's rule of 40 is 41% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Medanta's rule of X is 64% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Medanta and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 16% | XXX | 16% | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 25% | XXX | XXX | XXX |
| EBITDA Growth | 17% | XXX | 15% | XXX | XXX | XXX |
| Rule of 40 | 41% | XXX | 41% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 64% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $37K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 58% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Burjeel Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| PureHealth | XXX | XXX | XXX | XXX | XXX | XXX |
| Integral Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Ramsay Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Athens Medical Centre | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Medanta acquired XXX companies to date.
Last acquisition by Medanta was XXXXXXXX, XXXXX XXXXX XXXXXX . Medanta acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Medanta founded? | Medanta was founded in 2004. |
| Where is Medanta headquartered? | Medanta is headquartered in India. |
| How many employees does Medanta have? | As of today, Medanta has 6.8K+ employees. |
| Who is the CEO of Medanta? | Medanta's CEO is Mr. Pankaj Sahni. |
| Is Medanta publicy listed? | Yes, Medanta is a public company listed on BOM. |
| What is the stock symbol of Medanta? | Medanta trades under 543654 ticker. |
| When did Medanta go public? | Medanta went public in 2022. |
| Who are competitors of Medanta? | Similar companies to Medanta include e.g. Burjeel Holdings, PureHealth, Integral Diagnostics, Ramsay Health. |
| What is the current market cap of Medanta? | Medanta's current market cap is $3.7B |
| What is the current revenue of Medanta? | Medanta's last 12 months revenue is $443M. |
| What is the current revenue growth of Medanta? | Medanta revenue growth (NTM/LTM) is 16%. |
| What is the current EV/Revenue multiple of Medanta? | Current revenue multiple of Medanta is 8.3x. |
| Is Medanta profitable? | Yes, Medanta is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Medanta? | Medanta's last 12 months EBITDA is $106M. |
| What is Medanta's EBITDA margin? | Medanta's last 12 months EBITDA margin is 24%. |
| What is the current EV/EBITDA multiple of Medanta? | Current EBITDA multiple of Medanta is 34.7x. |
| What is the current FCF of Medanta? | Medanta's last 12 months FCF is $9.2M. |
| What is Medanta's FCF margin? | Medanta's last 12 months FCF margin is 2%. |
| What is the current EV/FCF multiple of Medanta? | Current FCF multiple of Medanta is 400.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
